Skip to main content

Advertisement

Log in

The role of the caregiver in older patients with advanced prostate cancer: results from the ADHERE Prospective Study of the Meet-URO network

  • Research
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

Abstract

Purpose

To assess caregivers’ characteristics and influence of the presence or absence of the caregiver on clinical outcomes of older (≥70 years) metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone (ABI) or enzalutamide (ENZ).

Methods

Patients from the Meet-URO 5 ADHERE study were assessed with a 5-item caregiver evaluation questionnaire focusing on the presence, age, degree of kinship, working status and qualification of the caregiver. We investigated the association between the presence of a caregiver and the clinical characteristics and outcomes of enrolled patients.

Results

No differences were found in the main clinical characteristics between patients with or without a caregiver, except for a lower median G8 score (p = 0.0453) in the caregiver group. A longer radiographic PFS (rPFS) was observed in the group without a caregiver, with a trend towards more prolonged overall survival (OS) in the same group.

Conclusion

Our work suggests a detrimental effect of caregivers in managing older mCRPC patients treated with ABI or ENZ, especially those identified as frail by the geriatric G8 screening score. Further work is needed to identify and address patients’ vulnerability areas, which could have a detrimental effect on prognosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

Data Availability

The data that support the findings of this study are not openly available and are available from the corresponding author upon reasonable request.

References

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424. https://doi.org/10.3322/caac.21492.

  2. Gillessen S, Armstrong A, Attard G, Beer TM, Beltran H, Bjartell A et al (2022) Management of patients with advanced prostate cancer: report from the advanced prostate cancer consensus conference 2021. Eur Urol 82(1):115–141

    Article  CAS  PubMed  Google Scholar 

  3. Rescigno P, Maruzzo M, Rebuzzi SE, Murianni V, Cinausero M, Lipari H et al (2022) Adherence to oral treatments in older patients with advanced prostate cancer, the ADHERE Study: a prospective trial of the Meet-URO network. Oncologist 27(12):e949–e956

    Article  PubMed  PubMed Central  Google Scholar 

  4. Banna GL, Basso U, Giunta EF, Fratino L, Rebuzzi SE, Buti S et al (2022) The geriatric G8 score is associated with survival outcomes in older patients with advanced prostate cancer in the ADHERE Prospective Study of the Meet-URO network. Curr Oncol 29(10):7745–7753

    Article  PubMed  PubMed Central  Google Scholar 

  5. Boyle HJ, Alibhai S, Decoster L, Efstathiou E, Fizazi K, Mottet N et al (2019) Updated recommendations of the International Society of Geriatric Oncology on prostate cancer management in older patients. Eur J Cancer 116:116–136

    Article  CAS  PubMed  Google Scholar 

  6. Hu Y, Liu T, Li F (2019) Association between dyadic interventions and outcomes in cancer patients: a meta-analysis. Support Care Cancer 27(3):745–761

    Article  PubMed  Google Scholar 

  7. Akgun-Citak E, Attepe-Ozden S, Vaskelyte A, van Bruchem-Visser RL, Pompili S, Kav S et al (2020) Challenges and needs of informal caregivers in elderly care: qualitative research in four European countries, the TRACE project. Arch Gerontol Geriatr 87:103971

    Article  PubMed  Google Scholar 

  8. Mackinnon CJ (2009) Applying feminist, multicultural, and social justice theory to diverse women who function as caregivers in end-of-life and palliative home care. Palliat Support Care 7(4):501–512

    Article  PubMed  Google Scholar 

  9. Cascella Carbó GF, García-Orellán R (2020) Burden and gender inequalities around informal care. Investig Educ Enferm 38(1):e10

    Google Scholar 

  10. Schrank B, Ebert-Vogel A, Amering M, Masel EK, Neubauer M, Watzke H et al (2016) Gender differences in caregiver burden and its determinants in family members of terminally ill cancer patients. Psychooncology 25(7):808–814

    Article  PubMed  Google Scholar 

  11. Yabroff KR, Kim Y (2009) Time costs associated with informal caregiving for cancer survivors. Cancer 115(18 Suppl):4362–4373

    Article  PubMed  Google Scholar 

  12. Nielsen MK, Neergaard MA, Jensen AB, Bro F, Guldin MB (2016) Psychological distress, health, and socio-economic factors in caregivers of terminally ill patients: a nationwide population-based cohort study. Support Care Cancer 24(7):3057–3067

    PubMed  Google Scholar 

  13. Williams AL (2018) Family caregivers to adults with cancer: the consequences of caring. Recent Results Cancer Res 210:87–103

    Article  PubMed  Google Scholar 

  14. Marshall VK, Vachon EA, Given BA, Lehto RH (2018) Impact of oral anticancer medication from a family caregiver perspective. Oncol Nurs Forum 45(5):597–606

    Article  PubMed  Google Scholar 

  15. Weitzner MA, Haley WE, Chen H (2000) The family caregiver of the older cancer patient. Hematol Oncol Clin North Am 14(1):269–281

    Article  CAS  PubMed  Google Scholar 

  16. Given B, Sherwood PR (2006) Family care for the older person with cancer. Semin Oncol Nurs 22(1):43–50

    Article  PubMed  Google Scholar 

  17. Piervil E, Odedina F, Young ME (2019) The role and influence of prostate cancer caregivers across the care continuum. Health Promot Pract 20(3):436–444

    Article  PubMed  Google Scholar 

  18. Schumacher FA, Helenowski IB, Oswald LB, Gonzalez BD, Benning JT, Morgans AK (2022) Treatment decision-making in metastatic prostate cancer: perceptions of locus of control among patient, caregiver, and physician triads. Patient Prefer Adherence 28(16):235–244

    Article  Google Scholar 

  19. National Alliance for Caregiving (2016) Cancer caregiving in the U.S.: an intense, episodic, and challenging care experience. National Alliance for Caregiving, Bethesda, MD https://www.caregiving.org/wp-content/uploads/2020/05/CancerCaregivingReport_FINAL_June-17-2016.pdf Accessed on 01 Dec 2022

    Google Scholar 

  20. O'Brien ME, Steele NM (2017) Wife caregiver experiences in the patient with prostate cancer at home. Urol Nurs 37(1):37–44

    Article  PubMed  Google Scholar 

  21. Rha SY, Park Y, Song SK, Lee CE, Lee J (2015) Caregiving burden and the quality of life of family caregivers of cancer patients: the relationship and correlates. Eur J Oncol Nurs 9(4):376–382

    Article  Google Scholar 

  22. LeBlanc TW, Bloom N, Wolf SP, Lowman SG, Pollak KI, Steinhauser KE et al (2018) Triadic treatment decision-making in advanced cancer: a pilot study of the roles and perceptions of patients, caregivers, and oncologists. Support Care Cancer 26(4):1197–1205

    Article  PubMed  Google Scholar 

  23. Dionne-Odom JN, Hull JG, Martin MY, Lyons KD, Prescott AT, Tosteson T et al (2016) Associations between advanced cancer patients' survival and family caregiver presence and burden. Cancer Med 5(5):853–862

    Article  PubMed  PubMed Central  Google Scholar 

  24. Jang SN, Avendano M, Kawachi I (2012) Informal caregiving patterns in Korea and European countries: a cross-national comparison. Asian Nurs Res (Korean Soc Nurs Sci) 6(1):19–26

    PubMed  Google Scholar 

  25. Romito F, Goldzweig G, Cormio C, Hagedoorn M, Andersen BL (2013) Informal caregiving for cancer patients. Cancer. 119(Suppl 11(0 11)):2160–2169

    Article  PubMed  Google Scholar 

  26. ISDOC Working Group, Giorgi Rossi P, Beccaro M, Miccinesi G, Borgia P, Costantini M, Chini F et al (2007) Dying of cancer in Italy: impact on family and caregiver. The Italian Survey of Dying of Cancer. J Epidemiol Community Health 61(6):547–554

    Article  Google Scholar 

Download references

Funding

S.E.R. and G.F. would like to thank the Italian Ministry of Health (Ricerca Corrente 2018–2021 grants), which financially supports their current research on identifying prognostic and predictive markers for patients with genitourinary tumours. P.R.’s work is funded by Prostate Cancer Foundation through a PCF YI award and by the FPRC 5 PER MILLE—Ministero della Salute 2017—PTCRC SEE PROS ONCOLOGIA and ‘Italian Ministry of Health, Ricerca Corrente 2022’.

Author information

Authors and Affiliations

Authors

Contributions

E.F.G.: conceptualization, data collection, methodology, statistical analysis, writing, figures and tables; S.D.P.: conceptualization, data collection, methodology; S.A.: writing; U.D.G.: methodology, review and editing; M.M., S.E.R., M.C., H.L., T.G., D.B., A.D., P.E., F.V., U.B., S.B., A.G., M.C., G.F.: data collection, review and editing; L.F.: conceptualization, methodology, data collection, review and editing; P.R.: conceptualization, methodology, review and editing; G.L.B.: conceptualization, data collection, methodology, review and editing.

Corresponding author

Correspondence to Pasquale Rescigno.

Ethics declarations

Ethics approval

The study was approved by the Catania-1 ethical committee (n.12/2019/CA of the 15th of February 2019). The study was performed in accordance with the Good Clinical Practice guidelines of the International Conference on Harmonization and the Declaration of Helsinki.

Consent to participate

All patients provided the protocol written informed consent.

Consent for publication

Participants were informed that the questionnaire results would be used for publications and provided their consent.

Conflict of interest

Emilio Francesco Giunta received personal fees from Novartis and travel accommodation from Janssen. Ugo De Giorgi received honoraria for advisory boards or speaker fees for Pfizer, BMS, MSD, PharmaMar, Astellas, Bayer, Ipsen, Roche, Novartis, Clovis, GSK, AstraZeneca, institutional research grants from AstraZeneca, Sanofi and Roche. Sara Elena Rebuzzi received honoraria as a speaker at scientific events and travel accommodation from Amgen, GSK, BMS and MSD. Davide Bimbatti received personal fees for Talks or Advisory/Consultant Role from Ipsen, Astellas, Janssen, Novartis, BMS and MSD outside the submitted work. Giuseppe Fornarini serviced as advisory boards for Astellas, Janssen, Pfizer, Bayer, MSD and Merck and received travel accommodation from Astellas, Janssen and Bayer. Giuseppe Luigi Banna reported personal fees from Astellas and AstraZeneca. Pasquale Rescigno has served as a consultant/advisory board member for MSD and Astra Zeneca. The other authors declare that they have no conflict of interest.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Giunta, E.F., De Padova, S., Anpalakhan, S. et al. The role of the caregiver in older patients with advanced prostate cancer: results from the ADHERE Prospective Study of the Meet-URO network. Support Care Cancer 31, 425 (2023). https://doi.org/10.1007/s00520-023-07867-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s00520-023-07867-4

Keywords

Navigation